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Handling of Vaccinia virus represents a risk for labora-
tory-acquired infections, especially in individuals with-
out completed vaccination. We report the case of a
Vaccinia infection in a previously vaccinated researcher
working with various genetically modi¢ed strains. We
could con¢rm the infection by electron microscopy,
positive cell culture, virus-speci¢c PCR, sequence ana-
lysis, and viral neutralization test. The isolated virus
carried a functionally inactivated cytohesin-1 gene of
human origin, which had been shown to impair leuko-
cyte adhesion by interacting with the LFA/ICAM-1
axis. The immunomodulating nature of the inserted
construct might thus have added to the infectivity of
the virus.
We emphasize on the necessity of Vaccinia vaccination
in laboratory sta¡ working in the ¢eld. Key words:Vaccinia
virus/vaccination/cytohesin-1 gene. J Invest Dermatol 120:356^358,
2003
I
n 1980 the WHO declared the successful eradication of
naturally occurring smallpox infections, and vaccination
with Vaccinia virus is no longer mandatory. However, Vac-
cinia is widely used as vector in biomedical research and
increasingly for vaccination programs in tumor trials. Re-
cently, vaccination against smallpox has regained strong public
attention in the context of possible terror attacks using biological
warfare reagents (Moss, 1996; Cohen, 2001).
In the US and Canada, speci¢c recommendations exist for
army members and laboratory personal that conduct research in
the ¢eld of orthopoxvirus and molecular and cellular biology
using recombinant Vaccinia viruses (Williams and Cooper, 1993).
In contrast, mandatory guidelines are lacking in Europe and
work withVaccinia viruses does not necessitate previous vaccina-
tion (Isaacs, 2002).Therefore, young laboratory members who are
born after the cessation of public vaccination programs in 1972
may be at hazard to acquire a Vaccinia virus infection. Although
some occupational laboratory incidents with Vaccinia including
sting exposures have been reported, clinically overt infections
seem to be rare (Openshaw et al, 1991). Recently, an infection with
a recombinant Vaccinia-Rabies glycoprotein construct was re-
ported which occurred in a patient with chronic in£ammatory
skin disease after contact with a rabies vaccine bait (Rupprecht
et al, 2001).
We report here of a Vaccinia virus infection following labora-
tory exposure with a genetically modi¢ed strain in a laboratory
sta¡ member without personal history of atopy or chronic skin
disease who was vaccinated during childhood and who had
not been accidently injured. Interestingly, the Vaccinia strain
contained a construct that had been used to decrease leuko-
cyte adhesion by interacting with the LFA-1/ICAM-1 signaling
pathway.
CASE REPORT
The 40-year-old Caucasian male had been working at a research
department for over 10 years with genetically modi¢ed Vaccinia
virus strains carrying various inserts that had been introduced
into the virus speci¢c thymidine kinase gene. He had been vacci-
nated with Vaccinia at the age of 1 and 12 years in the upper arm
by standard scari¢cation procedures. After an interruption of
about 12 months he restarted his laboratory work and handled
several times infected cell cultures with high concentrations of
recombinantVaccinia virus (B109 plaque forming units (PFU)/ml).
Three days prior to presentation at our department he had no-
ticed the growth of a vesicular lesion at the distal phalanx of the
2nd ¢nger of his right hand, which slowly progressed to a
15-mm sized in¢ltrated in£ammatory nodule with central he-
morrhagic necrosis (Fig 1a,b). A second in£amed vesicular lesion
developed at the 3rd ¢nger of the left hand two days later. After
an unsuccessful surgical incision he presented at our department
for diagnosis and treatment.
The clinical appearance of a dark red raised ¢rm nodule with
central necrosis was suggestive for ortho- or parapoxvirus infec-
tion, e.g., cow-poxvirus or Orf virus. The patient denied recent
contact to cats, cows, or sheep but reported regular professional
contact to Vaccinia virus. General medical examination revealed
no abnormal results and the patient showed no signs of cellulitis
or lymphadenopathy. Only the palms of both hands showed
signs of mild skin barrier disturbance (e.g., small erosions) from
working with unprotected hands in cold temperature over a pro-
longed period. After informed consent was obtained, a skin
biopsy and serum samples were taken for microbiological, elec-
tron microscopy, and immunological analysis.
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The lesions were treated with topical disinfectants (such as
polyvidone iodine ointments) leading to complete healing of
skin lesions within two weeks.
METHODS
The biopsy was split for electron microscopy (EM) and viral culture for
orthopoxvirus using the permanent African green monkey kidney cell line
MA 104 cultured in minimal essential medium supplemented with 5%
fetal calf serum followed by molecular biology analysis.
In addition, serum samples were taken for antibody determination using
the virus neutralization assay. The test was performed following the meth-
od described by Czerny et al, using 100 plaque-forming units of orthopox-
virus strain Vaccinia Virus Munich 1 and MA 104 cells in 24-well Linbro
plates (Czerny et al, 1996). Plaques were visualized with crystal violet after
24 h of inoculation at 371C and 5% CO2.
Electron microscopy of infected cells was performed as previously de-
scribed (Pfe¡er et al, 1996). The isolated virus was further examined by
PCR. Brie£y, DNA was extracted from the infected cell culture as de-
scribed elsewhere (Meyer et al, 1994). DNA of the patients’ isolate,Vaccinia
virus reference strain Western Reserve (WR) and cowpoxvirus Brighton
(BR) was screened using a PCR targeting the A-type inclusion (ATI) pro-
tein gene (Meyer et al, 1994). The resultant fragments were digested with
BglII and separated on an agarose gel. The ATI-PCR assay is based on se-
quences £anking a region that exhibits various deletions in variola, vacci-
nia, mousepox, monkeypox and camelpox virus as compared to cowpox
virus. Thus, depending on which of the six species is being examined, the
ATI-PCR provides a DNA fragment of distinct size. In a second PCR
(VTK-PCR), an ampli¢cation of the thymidine kinase gene was carried
out as previously described (Thomas et al, 1990). Sequencing of the inserted
DNAwas performed using an ABI Prism 310 sequencer (Applied Biosys-
tems GmbH, PE Biosystems Weiterstadt, Germany), ¢rst with a primer
that allows identi¢cation of the inserted gene and second with a primer
located within the human cytohesin-1 gene which allows to uncover the
E157K mutation (see legends to Fig 2).
Figure1. A dark, ¢rm, hemorrhagic nodule seen at the
2nd ¢nger of the right hand. In addition, a second lesion
presenting as small papular-vesicular eruption was noted
at the 3rd ¢nger of the left hand.
Figure 2. PCR ampli¢cation of the thymidine kinase gene and sequencing of the inserted DNA fragment. (a) The following primers were used to amplify
a 1800-bp fragment of the thymidine kinase gene together with the inserted DNA fragment: VTK1: 50 -ATG AAC GGC GGA CATATT CAG TTG-30,
VTK2: 50 -TTATGA GTC GAT GTA ACA CTT TCT-30. (b) The DNA fragment was sequenced with the primers VTK3: 50 -CCA CTA CAC GCA GAA
GAG-30 and Cyt1: 50 -GCTGCATGAGTTCAC TGAT-30. Only parts of the sequences are shown:VTK3: upper line: part of the transmembrane Ig fusion
protein; bottom line: N-terminal nucleotide and amino acid sequence of the human cytohesin-1 gene. Cyt1: Partial nucleotide and amino acid sequence of
the SEC7 domain of cytohesin-1. The critical residue E157 which is mutated in this particular vector to a lysine is shown in bold. (c) Scheme of the
identi¢ed Vaccinia thymidine kinase (VTK) fusion protein casette containing human IgG1 and the sequence for cytohesin-1 with the E157 K mutation
responsible for the loss of function.
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RESULTS
EM analysis of the biopsy showed a single orthopoxvirus parti-
cle, a result further con¢rmed by EM of the infected cell culture,
which revealed multiple orthopoxvirus particles after the ¢rst
passage.
The fragment size obtained for the patients’ isolate andVaccinia
virus WR in the ATI-assay were identical and slightly smaller as
compared to cowpox virus BR. BglII digest electrophoresis was
used to further enhance fragment size motility and the resulting
patterns were identical for the obtained isolate and Vaccinia virus
WR but di¡erent from cowpox virus BR (data not shown). The
VTK-PCR utilizes primers £anking the insertion locus of the
thymidine kinase gene. A fragment of about 530 bp was ampli-
¢ed fromVaccinia virus WRwhich corresponds well to the size
(528 bp) described in the literature (Thomas et al, 1990). A frag-
ment of about 1800 bp (see Fig 2) was ampli¢ed from the ob-
tained patients’ sample indicating that the thymidine kinase gene
contains an insertion of approximately 1.3 kb. Further sequence
analysis revealed that the inserted DNA fragment encoded a fu-
sion protein of the human cytohesin-1 cDNAwith a transmem-
brane Ig sequence (Kolanus et al, 1996). The glutamic acid residue
at pos. 157 of cytohesin-1 was mutated to a lysine residue. E157
has been shown to be critical for catalytic activity and the muta-
tion to K leads to a complete loss of GEF (guanine exchange fac-
tor) activity. This mutant had been shown to impair leukocyte
adherence functions in cellular assays in a previous report (Geiger
et al, 2000).
Anti-Vaccinia antibodies evaluated in consecutive serum sam-
ples were elevated, showing a titer of 1:64, increasing to 1:256
three weeks later, an increase in antibodies which is usually not
observed 30 years after vaccination. Routine blood count para-
meters were found within normal limits.
DISCUSSION
We have documented a case of human infection by the geneti-
cally modi¢ed Vaccinia strain Western Reserve used for research
studies. Up to now there has been no report of clinical symptoms
in individuals exposed to genetically modi¢ed laboratory strains
without previous sting injury. Our patient developed two clini-
cally typical pox lesions although he had been vaccinated with
the highly similar Vaccinia strain twice during childhood. The
case presented here emphasizes the possible risk of clinical infec-
tions by laboratory strains even when they are handled properly
and no concomitant disruptions of the epidermal barrier are pre-
sent as seen in our patient.The duration of a protective immunity
after vaccination is a subject of current debate (Cohen, 2001). The
induced T-cell reactivity towards the Vaccinia virus seems to re-
main for decades (Demkowicz et al, 1996; Ennis et al, 2002). Since
the course of the infection in our patient was relatively mild with
no generalization or signs of systemic disease it is likely that he
had incomplete protective immunity from the vaccination 28
years ago. This might, however, not be the case for individuals
without Vaccinia-speci¢c immunity.
There is now an increasing number of young researchers and
students within the ¢eld of biomedical sciences who have not
been routinely vaccinated against smallpox, as most countries
stopped their vaccination programs in the 1970s. At present, no
general recommendation exists forVaccinia vaccination of labora-
tory workers.
The CDC gives a clear guideline by suggesting that ‘‘all per-
sons working in or entering laboratory or animal care areas
where activities with vaccinia, monkey pox, or cow pox viruses
are being conducted should have documented evidence of satis-
factory vaccination within the preceding 10 years.’’ (http://
bmbl.od.nih.gov/virall.htm#pox). The situation is less clear in
Europe. General recommendations do not exist and there is cur-
rently no licensed vaccination product available. It is questionable
whether the advantages of a general vaccination strategy
outweigh the risk of vaccination complications that have been
observed repeatedly (for a review see Isaacs, 2002). The case re-
ported here indicates that infections with genetically modi¢ed
strains can occur even when handled properly and argues in favor
of vaccination programs for laboratory sta¡.
However, the infectivity of the vaccinia construct may depend
on the insert. The VTK-PCR revealed that a cytohesin-1 fusion
protein was inserted into theVaccinia vector. Cytohesin-1 is a reg-
ulatory interaction partner of the b2 integrin aLb2 (LFA-1) and a
guanine exchange factor (GEF) for ADP ribosylation factor
(ARF)-GTPases (Kolanus et al, 1996). The identi¢ed E157K muta-
tion leads to a dominant negative construct that has been shown
to suppress the adhesion of human peripheral blood lymphocytes
to ICAM-1 (Geiger et al, 2000). Taking into account that cytohe-
sin-1 plays a crucial role as a regulator of LFA-1 activation and
LFA-1 dependent spreading of lymphoid cells, it is tempting to
speculate that the virus construct contributed to a locally dimin-
ished immune response. A similar phenomenon has not been re-
ported so far. However, one should remain alert whether or not
the infectivity of laboratory strains of Vaccinia virus is a¡ected by
the inserts.
Fortunately, the course of the disease in our patient was self-
limited. Yet, in more severe infections systemic treatment has to
be considered for patients with laboratory acquiredVaccinia virus
infection. Currently the CDC recommends the use of immuno-
globulins (VIG) for severe cases (ACIP, 2001). However, these im-
munoglobulins are not ubiquitously available and therefore the
use of cidofovir might be considered (De Clercq, 2002), as animal
studies have shown promising results.
We are grateful to Mrs Susanne Kampf, Institut f rˇ Pharmakologie undToxikologie,
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